FDA's Drug Development Tool Qualification Processes

The Alliance for Artificial Intelligence in Healthcare (AAIH) welcomes the opportunity to provide comment on FDA’s Qualification Process for Drug Development Tools Draft Guidance, issued December 2019. Click here to read the full response.

Previous
Previous

Alliance for Artificial Intelligence in Healthcare Releases “The Lifecycle of an AI System in Healthcare” Whitepaper

Next
Next

Opportunities for Digital Medicine and AI Healthcare in Cures 2.0